ERBB2 and breast carcinoma: To date, two small exploratory studies of PD-L2 as a marker of clinical outcome in TNBC and human epidermal growth factor receptor 2–positive breast cancer yielded largely inconclusive results,27,28 and PD-L2 has not been explored in ER+ breast cancer.